LifeStance Health Group (NASDAQ:LFST) Releases Earnings Results, Beats Expectations By $0.03 EPS

Key Points

• Strong second-quarter results: LifeStance reported EPS of $0.06, beating estimates by $0.03, while revenue rose 26.1% year over year to $435.35 million. Adjusted EBITDA nearly doubled to $66 million as visits increased 19%.
• 2026 outlook raised: Management now expects full-year revenue of $1.685 billion-$1.725 billion and Adjusted EBITDA of $215 million-$235 million, supported by clinician growth, productivity gains and expanding specialty services.
• Risks remain: Third-quarter Adjusted EBITDA is expected to decline sequentially as the company increases investments in technology and growth initiatives, while EHR implementation could temporarily reduce productivity. Recent insider selling, including large director transactions, may also weigh on investor sentiment.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) posted its earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.03, FiscalAI reports. The company had revenue of $435.35 million during the quarter, compared to analysts' expectations of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. LifeStance Health Group's quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.01) EPS.

Here are the key takeaways from LifeStance Health Group's conference call:

• Positive Sentiment: LifeStance reported strong second-quarter performance, with revenue up 26% to $435 million, visits rising 19% to 2.6 million, and Adjusted EBITDA nearly doubling to $66 million. Adjusted EBITDA margin reached 15.2%, up more than 500 basis points year over year.
• Positive Sentiment: Management raised full-year 2026 guidance, now projecting revenue of $1.685 billion-$1.725 billion and Adjusted EBITDA of $215 million-$235 million. The midpoint implies 20% revenue growth and a 13.2% Adjusted EBITDA margin.
• Positive Sentiment: Clinician additions and productivity remain key growth drivers, with 193 net clinicians added in the quarter to reach 8,542, while visits per average clinician increased 7% for the third consecutive quarter. Management said only about 70% of clinician-provided capacity is currently being utilized, indicating further runway.
• Positive Sentiment: Specialty services, including TMS and SPRAVATO, are expanding and generated roughly $50 million of revenue last year, with expected growth of about 40% in 2026. The company also sees significant opportunity from geographic expansion, tuck-in acquisitions, AI-enabled tools, and a planned 2027 EHR rollout.
• Negative Sentiment: Third-quarter Adjusted EBITDA guidance of $49 million-$59 million implies a sequential decline as LifeStance increases spending on technology, patient acquisition, clinical excellence, compensation, and support staff. Management also cautioned that the phased EHR implementation could cause a temporary productivity dip.

LifeStance Health Group Stock Performance

Shares of LFST stock traded up $0.18 on Friday, hitting $10.84. The company's stock had a trading volume of 3,793,084 shares, compared to its average volume of 3,253,660. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.38. The stock's 50 day moving average is $9.95 and its 200-day moving average is $8.05. LifeStance Health Group has a fifty-two week low of $3.90 and a fifty-two week high of $11.76. The company has a market capitalization of $4.20 billion, a PE ratio of 83.39 and a beta of 1.14.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: BTIG raises price target: BTIG Research raised its LFST price target from $15 to $16 and initiated a “buy” rating, implying substantial potential appreciation from the referenced $10.84 price. Benzinga price target report
• Positive Sentiment: Q2 earnings beat expectations: LifeStance reported adjusted earnings of $0.06 per share, exceeding the $0.03 consensus estimate, compared with a $0.01 loss in the year-earlier quarter. Revenue rose 26.1% year over year to approximately $435.4 million, ahead of the $414.6 million analyst forecast. LifeStance Q2 earnings report
• Positive Sentiment: Profitability improved sharply: Net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volume increased 19% and the clinician base grew 11% to 8,542, supporting the company’s growth outlook. LifeStance financial results release
• Positive Sentiment: Full-year outlook raised: Management increased 2026 revenue guidance to $1.685 billion-$1.725 billion, Center Margin guidance to $570 million-$594 million and adjusted EBITDA guidance to $215 million-$235 million. Third-quarter revenue is projected at $420 million-$440 million, above the $417.7 million consensus estimate.
• Positive Sentiment: Share repurchase authorization: The board approved a new program allowing up to $100 million of common-stock repurchases, potentially supporting per-share results and signaling management confidence in the company’s valuation.
• Neutral Sentiment: Balance-sheet considerations: LifeStance generated $99.9 million of operating cash flow in Q2 and ended the period with $225.9 million in cash, but reported $259.0 million of net long-term debt.
• Negative Sentiment: Insider selling remains a risk: Recent disclosed insider activity has consisted entirely of sales, including substantial transactions by TPG-related entities and company executives. Continued selling could temper investor enthusiasm despite the strong operating results.

Insider Buying and Selling

In other LifeStance Health Group news, Director Eric Shuey sold 243,362 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the transaction, the director owned 867,562 shares in the company, valued at $6,957,847.24. This represents a 21.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Darren M. Black sold 5,899,661 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the transaction, the director owned 23,310,115 shares in the company, valued at approximately $186,947,122.30. The trade was a 20.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 7,612,394 shares of company stock valued at $62,938,451. 3.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company's stock worth $26,363,000 after acquiring an additional 1,839,465 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company's stock worth $45,998,000 after acquiring an additional 1,790,694 shares in the last quarter. Integral Health Asset Management LLC increased its stake in LifeStance Health Group by 100.0% in the fourth quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company's stock valued at $21,120,000 after acquiring an additional 1,500,000 shares during the last quarter. Barclays PLC increased its stake in LifeStance Health Group by 74.7% in the third quarter. Barclays PLC now owns 3,508,552 shares of the company's stock valued at $19,297,000 after acquiring an additional 1,499,687 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in LifeStance Health Group in the third quarter valued at approximately $7,637,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on LFST. The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a report on Friday, June 5th. They issued a "neutral" rating and a $9.00 price target on the stock. Zacks Research cut LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. Weiss Ratings restated a "hold (c-)" rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. KeyCorp upped their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Finally, Wall Street Zen lowered LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of "Moderate Buy" and a consensus target price of $11.62.

LifeStance Health Group Company Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source